dopamine beta monooxygenase Inhibitors
2 drugsAbout dopamine beta monooxygenase
Dopamine beta-monooxygenase (DBH) is an enzyme that catalyzes the conversion of dopamine to norepinephrine, a crucial step in catecholamine neurotransmitter synthesis. It plays a vital role in regulating sympathetic nervous system activity.
DBH's role in neurotransmitter synthesis makes it a potential target for pharmacological intervention. Currently, there is no genetic evidence data available linking DBH to specific diseases.
DBH is targeted by two FDA-approved small molecule drugs, MULTRYS and TRALEMENT, both marketed by AM REGENT. These drugs are approved for therapeutic areas outside of common indications.
Top dopamine beta monooxygenase Drugs
AM REGENT is the only company with approved drugs targeting DBH.
Low competition represents an opportunity, but also a risk due to lack of validation.
dopamine beta monooxygenase Drug Modality Landscape
Modalities
Routes of Administration
dopamine beta monooxygenase is druggable by small molecules, though no oral formulations are currently approved.
Explore alternative modalities like antibodies to differentiate from existing therapies.
dopamine beta monooxygenase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on dopamine beta monooxygenase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
dopamine beta monooxygenase Drug Approval Timeline (2020 - 2020)
The first drug targeting DBH was approved in 2020, with the most recent in the same year.
Recent approvals suggest renewed interest, but limited timeline indicates early market stage.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on dopamine beta monooxygenase. A trial counts if an approved drug acting on dopamine beta monooxygenase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.